ME00569A - Improved mycoplasma hyopneumoniae bacterin vaccine - Google Patents

Improved mycoplasma hyopneumoniae bacterin vaccine

Info

Publication number
ME00569A
ME00569A MEP-858/08A MEP85808A ME00569A ME 00569 A ME00569 A ME 00569A ME P85808 A MEP85808 A ME P85808A ME 00569 A ME00569 A ME 00569A
Authority
ME
Montenegro
Prior art keywords
mycoplasma hyopneumoniae
immunity
provides
administration
mixture
Prior art date
Application number
MEP-858/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Hsien-Jue Chu
Wumin Li
Zhichang Xu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32680190&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME00569(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of ME00569B publication Critical patent/ME00569B/me
Publication of ME00569A publication Critical patent/ME00569A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MEP-858/08A 2002-05-17 2003-05-14 Improved mycoplasma hyopneumoniae bacterin vaccine ME00569A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/150,597 US7018638B2 (en) 2000-12-19 2002-05-17 Mycoplasma hyopneumoniae bacterin vaccine
PCT/US2003/015115 WO2004058142A2 (en) 2002-05-17 2003-05-14 Improved combine vaccine against mycoplasma hyopneumoniae and porcine viruses

Publications (2)

Publication Number Publication Date
ME00569B ME00569B (me) 2011-12-20
ME00569A true ME00569A (en) 2011-12-20

Family

ID=32680190

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-858/08A ME00569A (en) 2002-05-17 2003-05-14 Improved mycoplasma hyopneumoniae bacterin vaccine

Country Status (19)

Country Link
US (4) US7018638B2 (me)
EP (2) EP1506006B1 (me)
JP (2) JP2006515304A (me)
KR (1) KR101056622B1 (me)
CN (1) CN1305524C (me)
AR (1) AR039545A1 (me)
AU (1) AU2003303129B2 (me)
BR (1) BR0310082A (me)
CL (1) CL2010000397A1 (me)
DK (1) DK1870109T3 (me)
ES (2) ES2569063T3 (me)
HR (1) HRP20041068B1 (me)
ME (1) ME00569A (me)
MX (1) MXPA04011218A (me)
NZ (1) NZ537014A (me)
RS (1) RS54390B1 (me)
TW (1) TWI320715B (me)
WO (1) WO2004058142A2 (me)
ZA (1) ZA200410153B (me)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39494E1 (en) * 1992-02-27 2007-02-27 Intervet Inc. Inactivated mycoplasma hyopneumoniae and uses therefor
DE69535059T2 (de) * 1994-04-11 2007-01-18 Wyeth Holdings Corp. Borrelia burgdorferi bacterin
US20040224327A1 (en) * 1996-10-30 2004-11-11 Meulenberg Johanna Jacoba Maria Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
EP0839912A1 (en) * 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
JP3961222B2 (ja) * 1999-03-08 2007-08-22 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー Ｐｒｒｓｖワクチン
MXPA01010681A (es) * 1999-04-22 2003-08-20 Us Agriculture Vacuna de sindrome respiratorio y reproductiva porcina a base de ja-142 aislado.
MY128159A (en) * 2000-06-30 2007-01-31 Wyeth Corp Methods and composition for oral vaccination
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
TWI238721B (en) * 2003-06-20 2005-09-01 Animal Technology Inst Taiwan Swine enzootic vaccine, its producing method and usage
KR20070028547A (ko) * 2004-06-18 2007-03-12 리전츠 오브 더 유니버스티 오브 미네소타 바이러스에 감염되고 백신접종된 생물의 동정
US7632636B2 (en) * 2004-09-21 2009-12-15 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome isolates and methods of use
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
US20060251827A1 (en) * 2005-05-09 2006-11-09 Applied Materials, Inc. Tandem uv chamber for curing dielectric materials
SI1904631T1 (sl) 2005-06-24 2012-09-28 Univ Minnesota Virusi PRRS, infekciozni kloni, njihovi mutanti in postopki uporabe
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2628158C (en) * 2005-11-04 2015-12-15 Novartis Vaccines And Diagnostics S.R.L. Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
AU2006310336B2 (en) 2005-11-04 2011-02-03 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
SG170792A1 (en) * 2005-12-29 2011-05-30 Boehringer Ingelheim Vetmed Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs
DK1968630T5 (en) * 2005-12-29 2018-08-13 Boehringer Ingelheim Vetmedica Inc MULTIVALENT PCV2 IMMUNOGENIC COMPOSITIONS.
DK2007419T3 (da) * 2006-04-10 2012-03-19 Intervet Int Bv Vaccine mod mycoplasma PRRSV
EP2101815A4 (en) 2006-12-11 2010-10-06 Boehringer Ingelheim Vetmed Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
WO2008076915A2 (en) 2006-12-15 2008-06-26 Boehringer Ingelheim Vetmedica, Inc. Treatment of pigs with pcv2 antigen
EP1941903A1 (en) * 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
CL2008001806A1 (es) * 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7829274B2 (en) * 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
AU2012261741B2 (en) * 2007-11-06 2016-02-25 Zoetis Services Llc Mycoplasma hyopneumoniae avirulent-adjuvanted live vaccine
WO2009061798A1 (en) 2007-11-06 2009-05-14 Wyeth Mycoplasma hyopneumoniae avirulent -adjuvanted live vaccine
CA2710558A1 (en) * 2007-12-31 2009-07-16 Boehringer Ingelheim Vetmedica, Inc. Pcv2 orf2 virus like particle with foreign amino acid insertion
CN101980720A (zh) * 2008-01-23 2011-02-23 贝林格尔.英格海姆维特梅迪卡有限公司 Pcv2猪肺炎支原体致免疫组合物及其制备方法
US20110033495A1 (en) * 2008-02-15 2011-02-10 Boehringer Ingelheim Vetmedica, Inc. Methods and compositions for reducing the impact of enteric diseases
US8444989B1 (en) * 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
CN101363865B (zh) * 2008-05-26 2013-03-06 北京庄笛浩禾生物医学科技有限公司 一种猪蓝耳病毒胶体金检测试纸条、其制备方法及其应用
JP5627581B2 (ja) * 2008-06-25 2014-11-19 ブラーシュ・バイオテック・エルエルシー ソマトスタチン免疫原性増進のための組成物および方法
US20100003278A1 (en) * 2008-07-03 2010-01-07 Boehringer Ingelheim Vetmedica, Inc. Immunological Compositions Effective for Lessening the Severity or Incidence of PRRSV Signs and Methods of Use Thereof
BRPI0917887A2 (pt) * 2008-08-25 2019-09-03 Boehringer Ingelheim Vetmedica Inc vacina contra síndrome reprodutiva e respiratória suína altamente patogênica (hp pprs)
WO2010092479A2 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with reduced amounts of squalene
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
EP2609428B1 (en) * 2010-08-27 2016-02-10 Intervet International B.V. Potency test for vaccine formulations
CN101954079B (zh) * 2010-09-21 2012-11-28 江苏省农业科学院 猪支原体肺炎活疫苗的疫苗佐剂及其制备方法和应用
DK2675475T3 (en) 2011-02-17 2015-09-14 Boehringer Ingelheim Vetmed NEW EUROPEAN PRRSV TRIAL
MY183980A (en) 2011-02-17 2021-03-17 Boehringer Ingelheim Vetmedica Gmbh Commercial scale process for production of prrsv
SI2691530T1 (en) 2011-06-10 2018-08-31 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US9315781B2 (en) 2011-07-29 2016-04-19 Boehringer Ingelheim Vetmedica Gmbh Infectious CDNA clone of european PRRS virus and uses thereof
US9187731B2 (en) 2011-07-29 2015-11-17 Boehringer Ingelheim Vetmedica Gmbh PRRS virus inducing type I interferon in susceptible cells
CN103157100B (zh) * 2011-12-08 2014-09-24 普莱柯生物工程股份有限公司 副猪嗜血杆菌病、猪链球菌病二联灭活疫苗及其制备方法
US9474692B2 (en) * 2012-01-13 2016-10-25 Boehringer Ingelheim Vetmedica Gmbh Kit for the preparation of a vaccinating agent
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
US9878027B2 (en) * 2012-12-28 2018-01-30 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition comprising mycoplasma antigens
EP2938747B1 (en) 2012-12-28 2019-05-01 Boehringer Ingelheim Vetmedica GmbH Method of making a mycoplasma vaccine
CN103908665B (zh) * 2013-01-05 2016-05-25 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
CN103071151B (zh) * 2013-01-17 2014-07-23 江苏省农业科学院 猪支原体肺炎疫苗专用稀释剂及其制备方法
CN103961695B (zh) * 2013-02-06 2016-09-07 普莱柯生物工程股份有限公司 一种预防和治疗猪呼吸道综合征的疫苗组合物及其制备方法和应用
CN105073130A (zh) 2013-03-15 2015-11-18 勃林格殷格翰动物保健公司 猪生殖与呼吸综合征病毒、组合物、疫苗及使用方法
CN104096222B (zh) * 2013-04-08 2016-09-14 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
PL2994162T3 (pl) 2013-05-08 2021-10-18 Pharmgate Biologics Inc. Szczepionka przeciwko pcv2 i mykoplazmie
MX373669B (es) 2013-09-25 2020-04-02 Zoetis Services Llc Composicion de vacuna de circovirus porcino tipo 2b divergente y procedimientos de uso.
CN105658660A (zh) 2013-10-02 2016-06-08 勃林格殷格翰动物保健公司 Pcv2 orf2蛋白变体和由其组成的病毒样颗粒
CN104248759B (zh) * 2013-11-19 2017-05-10 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
CN104857508B (zh) * 2014-02-21 2018-03-16 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
US10064930B2 (en) * 2015-01-16 2018-09-04 Boehringer-Ingelheim Vermedica, Inc. Immunogenic compositions and methods for pigeon fever
EP4588579A3 (en) * 2015-11-13 2025-10-22 Targan Inc. System and method of determining the health & gender of a chick
CN111346224B (zh) 2018-12-24 2023-12-08 洛阳赛威生物科技有限公司 一种免疫佐剂组合物及其制备方法和应用
CN112618710B (zh) * 2019-09-24 2023-09-29 华南理工大学 一种植物糖原猪口服接种疫苗纳米佐剂及其制备方法与应用
TW202510910A (zh) * 2023-06-28 2025-03-16 國立感染症研究所長代表之日本國 疫苗佐劑組成物及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3790665A (en) * 1968-02-23 1974-02-05 Haver Lockhart Labor Inc Injectable adjuvant,method of preparing same and compositions including such adjuvant
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPH0832637B2 (ja) * 1985-02-14 1996-03-29 アクゾ・エヌ・ヴエー 合成免疫原
ZA881694B (en) 1987-03-17 1988-09-06 Akzo N.V. Adjuvant mixture
EP0315153B1 (en) 1987-11-03 1994-05-11 Syntex (U.S.A.) Inc. Vaccine adjuvant
ZA906806B (en) * 1989-08-31 1991-06-26 Ici Australia Operations Plants
ES2112274T5 (es) * 1990-05-29 2006-03-01 Wyeth Holdings Corporation Vacuna contra la pneumonia en cerdos y metodo para la preparacion de la misma.
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
NZ285324A (en) 1994-05-10 1998-08-26 American Home Prod Vaccine containing modified live bovine respiratory syncytial virus (brsv) with an adjuvant and pharmaceutically acceptable carrier
US6517843B1 (en) * 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
UA78180C2 (uk) * 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US6632439B2 (en) * 1999-09-29 2003-10-14 Novartis Animal Health, Inc. Fusobacterium necrophorum vaccine and method for making such vaccine
US6585981B1 (en) * 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine

Also Published As

Publication number Publication date
JP5700861B2 (ja) 2015-04-15
MXPA04011218A (es) 2005-02-14
HRP20041068A2 (en) 2004-12-31
ES2569063T3 (es) 2016-05-06
HK1111103A1 (en) 2008-08-01
AR039545A1 (es) 2005-02-23
US20030017171A1 (en) 2003-01-23
WO2004058142A3 (en) 2004-11-04
ME00569B (me) 2011-12-20
JP2013189438A (ja) 2013-09-26
US7018638B2 (en) 2006-03-28
KR20050007402A (ko) 2005-01-17
US20070134269A1 (en) 2007-06-14
EP1506006A2 (en) 2005-02-16
NZ537014A (en) 2009-09-25
US7959927B2 (en) 2011-06-14
BR0310082A (pt) 2007-04-10
EP1870109A1 (en) 2007-12-26
US7622124B2 (en) 2009-11-24
US20100062018A1 (en) 2010-03-11
EP1870109B1 (en) 2016-03-16
RS99704A (sr) 2006-12-15
ZA200410153B (en) 2014-07-30
US7169394B2 (en) 2007-01-30
HRP20041068B1 (hr) 2018-10-05
CN1305524C (zh) 2007-03-21
EP1506006B1 (en) 2013-07-31
JP2006515304A (ja) 2006-05-25
CN1652817A (zh) 2005-08-10
TW200306854A (en) 2003-12-01
RS54390B1 (sr) 2016-04-28
KR101056622B1 (ko) 2011-08-16
ES2431988T3 (es) 2013-11-29
AU2003303129A1 (en) 2004-07-22
AU2003303129B2 (en) 2009-10-08
CL2010000397A1 (es) 2010-10-15
DK1870109T3 (en) 2016-04-25
US20060228373A1 (en) 2006-10-12
WO2004058142A2 (en) 2004-07-15
TWI320715B (en) 2010-02-21

Similar Documents

Publication Publication Date Title
ME00569A (en) Improved mycoplasma hyopneumoniae bacterin vaccine
ME00570A (en) Improved mycoplasma hyopneumoniae bacterin vaccine
ES2149361T3 (es) Vacuna viva modificada contra el brsv, mejorada.
WO2003055513A3 (en) Bacillus subtilis spores to stimulate the immune responses
PT1104306E (pt) Composicoes de cpg e adjuvantes de saponina e seus metodos
LU91778I2 (fr) Menveo - vaccin méningococcique des groupes A,C, W135 et Y conjugué.
WO2000050006A3 (en) Microemulsions with adsorbed macromoelecules and microparticles
MXPA05013973A (es) Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
UA98812C2 (ru) Авирулентная активированная живая вакцина mycoplasma hyopneumoniae
ATE398461T1 (de) Impstoffe zur transkutanen immunisierung gegen reisediarrhö
MX2010007815A (es) Composiciones inmunogenicas de mycoplasma hyopneumoniae contra pcv2 y metodos para producir composiciones de este tipo.
NO20091022L (no) Vaksine omfattende en olje i vann emulsjons-adjuvant
TW200722101A (en) Novel composition
BR0310042A (pt) Vacinas de combinação mucosal para meningite bacteriana
MX9303992A (es) Mutantes de eliminacion como vacunas para el colera.
EP1467771A4 (en) MYCOBACTERIAL VACCINE
AU5162201A (en) Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
WO2021255690A3 (en) Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
BR0112792A (pt) Bacterina, preparação de vacina, e, métodos para proteger um suìno suscetìvel contra a colonização ou infecção de uma mycoplasma hyopneumoniae e para induzir uma resposta imune em um suìno suscetìvel contra a pneumonia micoplasmática causada por uma mycoplasma hyopneumoniae
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
DK0757556T3 (da) Borrelia Burgdorferi-bakterin
DK0863981T3 (da) Detektering, forebyggelse og behandling af papillomatous digital dermatitis
Wui et al. A combination of the TLR4 agonist CIA05 and alum promotes the immune responses to Bacillus anthracis protective antigen in mice